Trial Profile
A Study Assessing Correlation Between Changes In Tumor Arterial Enhancement On Contrast-Enhanced Computed Tomography (CT)With Overall Survival (OS) In Patients With Hepatocellular Carcinoma(HCC) Treated With Sorafenib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 26 Apr 2017 New trial record